In 2016, osimertinib received the European Medicines Agency (EMA) approval for the treatment of patients with advanced/metastatic EGFR T790M mutation-positive NSCLC, based on AURA studies [16,17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.